The incidence of TA-GvHD in immunocompromised patients receiving blood transfusions is estimated to be 0.1 - 1.0%, and mortality around 80 - 90%.
TA-GvHD在免疫機能不全患者接受輸血之發生率約為0.1-1.0%，而死亡率約為80-90%。